Safety, tolerability and drug interactions of adjuvant imatinib mesylate (Gleevec) within the first 100 days following stem cell transplantation in patients with PH+ CML and PH+ all at high risk for recurrence
BLOOD（2003）
Key words
drug interaction
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined